Neoadjuvant Chemotherapy Response Prediction on Multi-center TURBT slides (5-fold cross-val) benchmark leaderboard · SOTA2 Research

Neoadjuvant Chemotherapy Response Prediction on Multi-center TURBT slides (5-fold cross-val)

77.35AUCACMIL + DA-Conv1d + SSL

Evaluation Results

Method	Links
ACMIL + DA-Conv1d + SSL2025.12		77.35	71.47	79.5	67.95	59.74	65.08
ACMIL + DA-MLP + SSL2025.12		77.28	75.13	66.91	79.68	64.44	63.93
ACMIL + DA-Conv1d + SSL2025.12		77.03	72.9	76.67	71.3	59.68	65.8
ACMIL + DA-Conv1d2025.12		76.86	73.89	63.98	79.22	61.44	61.88
ACMIL + DA-MLP + SSL2025.12		76.72	70.98	81.25	66.36	56.2	65.28
ACMIL + DA-MLP + SSL2025.12		76.57	70.82	51.34	79.78	47.62	48.06
ACMIL + DA-Conv1d2025.12		76.38	71.13	76.16	68.34	55.88	63.98
ACMIL + DA-MLP2025.12		76.22	72.23	68.75	73.25	57.73	62.26
ACMIL + DA-MLP + SSL2025.12		75.85	72.27	75.85	68.13	57.4	64.91
ACMIL + DA-Conv1d + SSL2025.12		75.47	72.61	69.65	73.28	58.97	62.96
ACMIL + DA-MLP + SSL2025.12		75	70.25	69.96	69.81	56.26	60.81
ACMIL + DA-Conv1d + SSL2025.12		74.72	68.87	75.59	66.14	54.04	61.78
ACMIL + DA-MLP2025.12		74.71	67.65	72.75	66.76	56.72	60.18
ACMIL + DA-MLP2025.12		74.63	69.53	70.76	71.34	59.35	61.6
ACMIL + DA-MLP2025.12		74.52	71.23	58.78	78.51	60.3	57.25
ACMIL + DA-MLP2025.12		74.35	71.75	74.84	69.42	56.05	63.9
ACMIL + DA-Conv1d2025.12		74.29	71.79	73.38	69.77	57.92	63.93
ACMIL + DA-Conv1d + SSL2025.12		74.09	70.03	74	67.86	54.81	62.13
ACMIL2025.12		73.78	70.42	67.57	71.72	56.79	60.93
ACMIL + DA-Conv1d2025.12		73.76	68.04	79.07	62.86	54.35	62
ACMIL + DA-Conv1d2025.12		73.69	73.41	71.65	73.99	60.54	64.92
ACMIL2025.12		73.37	67.59	69.16	66.69	55.66	58.31
ACMIL2025.12		72.92	70.57	64.49	76.16	62.14	60.31
ACMIL2025.12		72.42	68.03	74.95	64.23	60.12	65.54
ACMIL2025.12		71.94	67.12	74.13	65.05	57.59	61.61
ACMIL + RRT2025.12		70.34	70.6	65.91	71.63	56.37	59.96
ACMIL + RRT2025.12		64.59	61.53	48.83	71.21	44.87	42.45
ACMIL2025.12		60.73	58.28	76.9	47.21	45.63	55.23
ABMIL2025.12		57.95	61.42	7.25	91.68	9.22	7.6